Evidence map›Paper›PMID 27307695›Full record

ArticleMolecular vision2016

Serum molecular signature for proliferative diabetic retinopathy in Saudi patients with type 2 diabetes.

Jianbo Pan, Sheng Liu, Michael Farkas, Mark Consugar, Donald J Zack, Igor Kozak, J Fernando Arevalo, Eric Pierce, Jiang Qian, Eman Al Kahtani

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Molecular vision, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jianbo PanDepartment of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD.
Sheng LiuDepartment of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD.
Michael FarkasOcular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; Berman-Gund Laboratory for the Study of Retinal Degenerations, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.
Mark ConsugarOcular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; Berman-Gund Laboratory for the Study of Retinal Degenerations, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.
Donald J ZackDepartment of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD.
Igor KozakVitreoretina Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Kingdom of Saudi Arabia.
J Fernando ArevaloDepartment of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD; Vitreoretina Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Kingdom of Saudi Arabia.
Eric PierceOcular Genomics Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; Berman-Gund Laboratory for the Study of Retinal Degenerations, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.
Jiang QianDepartment of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD.
Eman Al KahtaniVitreoretina Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Kingdom of Saudi Arabia.
Johns Hopkins University · USMassachusetts Eye and Ear Infirmary · USKing Khaled Eye Specialist Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe risk of vision loss from proliferative diabetic retinopathy (PDR) can be reduced with timely detection and treatment. We aimed to identify serum molecular signatures that might help in the early detection of PDR in patients with diabetes.

methodsA total of 40 patients with diabetes were recruited at King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia, 20 with extensive PDR and 20 with mild non-proliferative diabetic retinopathy (NPDR). The two groups were matched in age, gender, and known duration of diabetes. We examined the whole genome transcriptome of blood samples from the patients using RNA sequencing. We built a model using a support vector machine (SVM) approach to identify gene combinations that can classify the two groups.

resultsDifferentially expressed genes were calculated from a total of 25,500 genes. Six genes (CCDC144NL, DYX1C1, KCNH3, LOC100506476, LOC285847, and ZNF80) were selected from the top 26 differentially expressed genes, and a combinatorial molecular signature was built based on the expression of the six genes. The mean area under receiver operating characteristic (ROC) curve was 0.978 in the cross validation. The corresponding sensitivity and specificity were 91.7% and 91.5%, respectively.

conclusionsOur preliminary study defined a combinatorial molecular signature that may be useful as a potential biomarker for early detection of proliferative diabetic retinopathy in patients with diabetes. A larger-scale study with an independent cohort of samples is necessary to validate and expand these findings.

Indexed as

AgedBiomarkersDiabetes Mellitus, Type 2Diabetic RetinopathyFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedRisk FactorsRNAROC CurveSaudi ArabiaSensitivity and SpecificityBiomarkersRNA

Identifiers

PMID27307695
PMCPMC4902182
OpenAlexW2421809008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.